Resilience and efficiency for the nanotechnology supply chains underpinning COVID-19 vaccine development.

Nanotechnology facilitated the development and scalable commercialization of many SARS-CoV-2 vaccines. However, the supply chains underpinning vaccine manufacturing have demonstrated brittleness at various stages of development and distribution. Whereas such brittleness leaves the broader pharmacological supply chain vulnerable to significant and unacceptable disruption, strategies for supply chain resilience are being considered across government, academia, and industry. How such resilience is understood and parameterized, however, is contentious. Our review of the nanotechnology supply chain resilience literature, synthesized with the larger supply chain resilience literature, analyzes current trends in implementing and modeling resilience and recommendations for bridging the gap in the lack of quantitative models, consistent definitions, and trade-off analyses for nano supply chains.